scispace - formally typeset
A

Angelica M. Merlot

Researcher at University of Sydney

Publications -  31
Citations -  7418

Angelica M. Merlot is an academic researcher from University of Sydney. The author has contributed to research in topics: Cancer cell & Cancer. The author has an hindex of 21, co-authored 31 publications receiving 6527 citations. Previous affiliations of Angelica M. Merlot include University of New South Wales.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Unraveling the mysteries of serum albumin—more than just a serum protein

TL;DR: The intracellular localization of albumin was assessed in order to understand the mechanisms and pathways responsible for its uptake, distribution and catabolism in multiple tissues, and this is reviewed herein.
Journal ArticleDOI

Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease.

TL;DR: Major aspects of the journey of iron from its initial cellular uptake, its modes of trafficking within cells, to an overview of its downstream utilization in the cytoplasm and within mitochondria are discussed.
Journal ArticleDOI

Novel Chelators for Cancer Treatment: Where Are We Now?

TL;DR: The absorption of iron from the gut; its transport, metabolism, and homeostasis in mammals; and the molecular pathways involved are examined.
Journal ArticleDOI

Clinical development of targeted and immune based anti-cancer therapies

TL;DR: This review introduces targeted therapies to epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), human Epidermal Growth Factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK), BRAF, and the inhibitors of the T-cell mediated immune response, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1)/ PD-1 ligand (PD